Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST: Telavancin for Complicated Gram-Positive Skin Infections
NCT00061633Phase 2Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Jun 2003
- Primary completion
- Jan 2004
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of telavancin in Skin and Skin Structure Infection (SSSI), sponsored by Cumberland Pharmaceuticals. Started Jun 2003; status: completed.
02
Drugs
telavancin
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT00061633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061633.